Published in J Virol on October 01, 1999
Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol (2004) 1.23
Critical role of dendritic cells in mouse mammary tumor virus in vivo infection. J Virol (2007) 1.09
Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens. PLoS Pathog (2006) 0.93
Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle. J Virol (2003) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med (1985) 11.14
Antigen-specific interaction between T and B cells. Nature (1985) 10.64
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science (1991) 7.25
Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell (1990) 6.33
Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med (1989) 5.65
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 5.61
Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med (1990) 5.35
The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity (1998) 5.20
B cells turn off virgin but not memory T cells. Science (1992) 4.12
In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med (1997) 3.75
Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes. J Exp Med (1986) 3.74
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med (1992) 3.52
Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 3.38
Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med (1997) 2.95
Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science (1996) 2.95
Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med (1993) 2.92
A maternally inherited superantigen encoded by a mammary tumour virus. Nature (1991) 2.92
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
Susceptibility of human peripheral blood dendritic cells to infection by human immunodeficiency virus. J Gen Virol (1987) 2.38
Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med (1997) 2.33
T cell stimulation in vivo by lipopolysaccharide (LPS). J Exp Med (1997) 2.29
Replication of human immunodeficiency virus type 1 in primary dendritic cell cultures. Proc Natl Acad Sci U S A (1991) 2.25
Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med (1997) 2.14
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med (1996) 2.08
HIV-1 selection by epidermal dendritic cells during transmission across human skin. J Exp Med (1998) 2.02
Antigen uptake and presentation by dendritic leukocytes. Semin Immunol (1992) 1.90
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med (1993) 1.67
Correcting an immune-response deficiency by creating E alpha gene transgenic mice. Nature (1985) 1.67
Quantitative impact of thymic clonal deletion on the T cell repertoire. J Exp Med (1997) 1.64
Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production. J Exp Med (1997) 1.57
B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens. J Exp Med (1994) 1.56
Both a precursor and a mature population of dendritic cells can bind HIV. However, only the mature population that expresses CD80 can pass infection to unstimulated CD4+ T cells. J Immunol (1995) 1.52
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J Exp Med (1992) 1.45
Mouse mammary tumor virus: immunological interplays between virus and host. Adv Immunol (1997) 1.29
Correlation between the V beta 4+ CD8+ T-cell population and the H-2d haplotype. Immunogenetics (1990) 1.29
Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. Evidence for intercellular transfer of Mlsa. J Exp Med (1989) 1.26
A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med (1994) 1.25
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. J Immunol (1998) 1.21
Immunology. Memories are made of this? Nature (1994) 1.16
Synthesis of the precursor to avian RNA tumor virus internal structural proteins early after infection. Virology (1976) 1.11
Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med (1994) 1.09
Positive and negative selection of T cell receptor V beta domains controlled by distinct cell populations in the thymus. J Exp Med (1989) 1.01
Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J Virol (1997) 0.97
Antigen presentation by B lymphocytes to CD4+ T lymphocytes in vivo: importance for B lymphocyte and T lymphocyte activation. Semin Immunol (1992) 0.91
Proteolytic processing activates a viral superantigen. J Exp Med (1996) 0.91
Direct physical interaction involving CD40 ligand on T cells and CD40 on B cells is required to propagate MMTV. Immunity (1995) 0.90
In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen. J Virol (1996) 0.90
Proteolytic processing is required for viral superantigen activity. J Exp Med (1995) 0.89
Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions. AIDS Res Hum Retroviruses (1996) 0.88
The functions of antigen recognition in T cell-dependent B cell activation. Semin Immunol (1993) 0.85
Acquired Mls-1a-like clonal deletion in Mls-1b mice. J Exp Med (1992) 0.84
A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus. Eur J Immunol (1996) 0.81
Paracrine transfer of mouse mammary tumor virus superantigen. J Exp Med (1997) 0.81
From antigen presentation to T-cell activation. Res Immunol (1999) 0.80
Infection of terminally differentiated myotubes with Rous sarcoma virus (RSV): lack of DNA integration but presence of RSV mRNA. J Gen Virol (1992) 0.79
The primary in vivo immune response to Mls-1 (Mtv-7 sag). Route of injection determines the immune response pattern. Immunology (1994) 0.79
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins. J Gen Virol (1992) 0.76
Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol (1975) 6.84
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
Structural analysis of the capsid polypeptides of herpes simplex virus types 1 and 2. J Virol (1980) 3.95
Demonstration of globin messenger sequences in giant nuclear precursors of messenger RNA of avian erythroblasts. Proc Natl Acad Sci U S A (1973) 3.88
A molecular basis for MHC class II--associated autoimmunity. Science (1988) 3.75
Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells. Mol Cell Biol (1984) 3.15
The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell (1992) 3.11
The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A (1987) 2.77
The region of mouse mammary tumor virus DNA containing the long terminal repeat includes a long coding sequence and signals for hormonally regulated transcription. EMBO J (1982) 2.76
Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science (1992) 2.60
Synthesis of avian RNA tumor virus structural proteins. Cold Spring Harb Symp Quant Biol (1975) 2.55
Cloned mouse mammary tumor virus DNA is biologically active in transfected mouse cells and its expression is stimulated by glucocorticoid hormones. Cell (1981) 2.54
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 2.54
Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med (1993) 2.44
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med (1999) 2.15
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Glucocorticoid regulation of mouse mammary tumor virus: identification of a short essential DNA region. EMBO J (1983) 2.12
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
T cell recognition as the target for immune intervention in autoimmune disease. Cell (1989) 2.04
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 1.99
Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol (2001) 1.96
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med (1988) 1.89
Defective cleavage of a precursor polypeptide in a temperature-sensitive mutant of avian sarcoma virus. Virology (1976) 1.82
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol (2000) 1.82
Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 1.80
Characterization of endogenous and exogenous mouse mammary tumor virus proviral DNA with site-specific molecular clones. J Virol (1980) 1.80
Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor. Proc Natl Acad Sci U S A (1988) 1.75
Identical V beta T-cell receptor genes used in alloreactive cytotoxic and antigen plus I-A specific helper T cells. Nature (1985) 1.74
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med (1993) 1.67
The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today (1989) 1.66
Mutations affecting either generation or survival of cells influence the pool size of mature B cells. Immunity (1999) 1.61
Functional analysis of the glucocorticoid regulatory elements present in the mouse mammary tumor virus long terminal repeat. A synthetic distal binding site can replace the proximal binding domain. J Mol Biol (1986) 1.60
Isolation of poly(adenylic acid)-rich ribonucleic acid from mouse myeloma and synthesis of complementary deoxyribonucleic acid. Biochemistry (1973) 1.58
Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production. J Exp Med (1997) 1.57
Cytotoxic T cell clone-specific monoclonal antibodies used to select clonotypic antigen-specific cytotoxic T cells. Eur J Immunol (1985) 1.52
The generation of the two envelope glycoproteins of Rous sarcoma virus from a common precursor polypeptide. Virology (1978) 1.49
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity (2002) 1.49
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J Exp Med (1992) 1.45
Nucleotide sequence of the 5' noncoding region and part of the gag gene of mouse mammary tumor virus; identification of the 5' splicing site for subgenomic mRNAs. Nucleic Acids Res (1983) 1.45
Estimation of the number of genes coding for the constant part of the mouse immunoglobulin kappa light chain. Proc Natl Acad Sci U S A (1974) 1.42
A new site of integration for mouse mammary tumor virus proviral DNA common to BALB/cf(C3H) mammary and kidney adenocarcinomas. EMBO J (1986) 1.39
Cellular interactions involved in Th cell memory. J Immunol (2000) 1.38
Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol (2001) 1.38
Alterations in the U3 region of the long terminal repeat of an infectious thymotropic type B retrovirus. J Virol (1988) 1.33
Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med (2001) 1.32
A polymorphic microsatellite in the tumor necrosis factor alpha promoter identifies an allele unique to the NZW mouse strain. J Exp Med (1990) 1.31
Isolation and analysis of genomic DNA clones encoding the third component of mouse complement. Proc Natl Acad Sci U S A (1982) 1.30
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med (1993) 1.29
Mouse mammary tumor virus: immunological interplays between virus and host. Adv Immunol (1997) 1.29
Exogenous mouse mammary tumor virus proviral DNA isolated from a kidney adenocarcinoma cell line contains alterations in the U3 region of the long terminal repeat. J Virol (1986) 1.28
Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med (1994) 1.28
Identification of mouse mammary tumor virus-specific mRNA. J Virol (1979) 1.25
Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene (1996) 1.22
Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J Immunol (1999) 1.22
In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol (2000) 1.21
Sequence determination of the 3' end of mouse mammary tumor virus RNA. Mol Biol Rep (1981) 1.21
Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur J Immunol (2001) 1.21
Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther (2000) 1.20
Characterization of cloned cytotoxic lymphocytes with NK-like activity. J Immunol (1983) 1.18
Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. Immunol Today (2000) 1.15
Rifampicin inhibits focus formation in chick fibroblasts infected with Rous sarcoma virus. Nature (1969) 1.15
Extracellular cleavage of the glycoprotein precursor of Rous sarcoma virus. J Virol (1979) 1.14
Genomic location of mouse mammary tumor virus proviral DNA in normal mouse tissue and in mammary tumors. Cold Spring Harb Symp Quant Biol (1980) 1.14
Biosynthesis of an unglycosylated envelope glycoprotein of Rous sarcoma virus in the presence of tunicamycin. J Virol (1979) 1.12
Synthesis of the precursor to avian RNA tumor virus internal structural proteins early after infection. Virology (1976) 1.11
Mouse complement components C3 and C4. Characterization of their messenger RNA and molecular cloning of complementary DNA for C3. J Biol Chem (1981) 1.10
Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med (1994) 1.09
Transcription of the bacteriophage T4 template. Obligate synthesis of T4 prereplicative RNA in vitro. Biochemistry (1970) 1.08
Developmental dissociation of thymic dendritic cell and thymocyte lineages revealed in growth factor receptor mutant mice. Proc Natl Acad Sci U S A (1999) 1.08
Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol (2003) 1.06
Murine leukemia virus proteins expressed on the surface of infected cells in culture. J Virol (1980) 1.05
Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. J Immunol (1997) 1.04
Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir (Wien) (1990) 1.04
Dual function of a nuclear factor I binding site in MMTV transcription regulation. Nucleic Acids Res (1989) 1.04
Mouse mammary tumour virus related sequences are present in human DNA. Nucleic Acids Res (1983) 1.04
Functional comparison of thymic B cells and dendritic cells in vivo. Blood (2000) 1.03
Cloned endogenous mouse mammary tumor virus DNA is biologically active in transfected mouse cells and its expression is stimulated by glucocorticoid hormones. Virology (1982) 1.02
Establishment of two rabbit mammary epithelial cell lines with distinct oncogenic potential and differentiated phenotype after microinjection of transforming genes. Mol Cell Biol (1986) 1.00
Dexamethasone increases the number of RNA polymerase II molecules transcribing integrated mouse mammary tumor virus DNA and flanking mouse sequences. Mol Cell Biol (1984) 0.99
Use of a glucocorticoid-inducible promoter for expression of herpes simplex virus type 1 glycoprotein gC1, a cytotoxic protein in mammalian cells. Mol Cell Biol (1989) 0.98
Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J Virol (1997) 0.97
Developmental regulation of dendritic cell function. Curr Opin Immunol (1999) 0.94
The mouse mammary tumor virus long terminal repeat encodes a 47 kDa glycoprotein with a short half-life in mammalian cells. Mol Immunol (1993) 0.94
Differential migration of in vivo primed B and T lymphocytes to lymphoid and non-lymphoid organs. Eur J Immunol (2001) 0.92
New infectious mammary tumor virus superantigen with V beta-specificity identical to staphylococcal enterotoxin B (SEB). Eur J Immunol (1994) 0.91
B cell response after MMTV infection: extrafollicular plasmablasts represent the main infected population and can transmit viral infection. J Immunol (1999) 0.91
Prognostic implications of expression of the cellular genes myc, fos, Ha-ras and Ki-ras in colon carcinoma. Int J Cancer (1987) 0.90
In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen. J Virol (1996) 0.90
A new infectious mammary tumor virus in the milk of mice implanted with C4 hyperplastic alveolar nodules. Eur J Immunol (1993) 0.89
Superantigens in autoimmune diseases: still more shades of gray. Immunol Rev (1996) 0.89